Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2008 Jun 9;31(6):253–258. doi: 10.1002/clc.20181

Atorvastatin Administration after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease and Normal Lipid Profiles: Impact on Plasma Adiponectin Level

Kuei‐Chuan Chan 1, Hsi‐Hsien Chou 1, Chien‐Ning Huang 1,✉, Ming‐Chih Chou 1
PMCID: PMC6653046  PMID: 18543304

Abstract

Background

There is controversy about the effects of statins on plasma adiponectin, and the impact of percutaneous coronary intervention (PCI) on plasma adiponectin level is still unknown. We investigated the impact of Atorvastatin on plasma adiponectin levels in coronary artery disease (CAD) patients with stable angina and normal lipid profiles after PCI.

Methods

Sixty CAD patients with stable angina and normal lipid profiles scheduled for PCI, and not on statins, were randomly assigned to either no treatment (control group) or the Atorvastatin treatment (Atorvastatin group). Atorvastatin administration was started immediately after PCI. Blood samples were obtained immediately after PCI and again 3 and 6 mo later. Fasting plasma adiponectin concentrations were measured using a radioimmunoassay kit.

Results

After PCI, there were statistically significant decreases in adiponectin levels in the Atorvastatin group at 3 and 6 mo (8.66 ± 0.69 versus 6.87 ± 0.55 and 7.12 ± 0.71 µg/mL at 0, 3, and 6 mo, respectively), despite the anti‐inflammation and lipid‐lowering effects of Atorvastatin. There were no statistically significant changes in adiponectin levels in the control group. There was significant positive association between baseline plasma adiponectin and high‐density lipoprotein (HDL) levels. Changes of adiponectin level were not associated with the changes of high‐sensitivity C‐reactive protein (hs‐CRP) and lipid profiles in the Atorvastatin group.

Conclusions

Our study confirmed the benefits of Atorvastatin on anti‐inflammation and anti‐atherosclerosis, but we also found that Atorvastatin had a negative effect on the adiponectin system. The anti‐inflammatory, anti‐atherogenic effects of Atorvastatin are not affected by decreased adiponectin levels. Copyright © 2008 Wiley Periodicals, Inc.

Keywords: atorvastatin, adiponectin, coronary artery disease, percutaneous coronary intervention

Full Text

The Full Text of this article is available as a PDF (110.3 KB).

References

  • 1. Lindsay RS, Walker JD, Havel PJ, Hamilton BA, Calder AA, et al.: Scottish Multicentre Study of diabetes pregnancy: adiponectin is present in cord blood but is unrelated to birth weight. Diabetes Care 2003; 26: 2244–2249. [DOI] [PubMed] [Google Scholar]
  • 2. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, et al.: Novel modulator for endothelial adhesion molecules: adipocyte‐derived plasma protein adiponectin. Circulation 1999; 100: 2473–2476. [DOI] [PubMed] [Google Scholar]
  • 3. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, et al.: Adiponectin, metabolic risk fators, and cardiovascular events among patients with end‐stage renal disease. Am Soc Nephrol 2002; 13: 134–141. [DOI] [PubMed] [Google Scholar]
  • 4. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, et al.: Androgens decrease plasma adiponectin, an insulin‐sensitizing adipocyte‐derived protein. Diabetes 2002; 51: 2734–2741. [DOI] [PubMed] [Google Scholar]
  • 5. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, et al.: Weight reduction increases plasma levels of an adipose‐derived anti‐inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815–3819. [DOI] [PubMed] [Google Scholar]
  • 6. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, et al.,: Osaka CAD Study Group : Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85–89. [DOI] [PubMed] [Google Scholar]
  • 7. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930–1935. [DOI] [PubMed] [Google Scholar]
  • 8. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, et al.: Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226–228. [DOI] [PubMed] [Google Scholar]
  • 9. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, et al.: Adiponectin and development of type 2 diabetes in the Pima India population. Lancet 2002; 360: 57–58. [DOI] [PubMed] [Google Scholar]
  • 10. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, et al.: Paradoxical decrease of an adipose‐specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79–83. [DOI] [PubMed] [Google Scholar]
  • 11. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, et al.: PPAR γligands increase expression and plasma concentrations of adiponectin, an adipose‐derived protein. Diabetes 2001; 50: 2094–2099. [DOI] [PubMed] [Google Scholar]
  • 12. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, et al.: Synthetic peroxisome proliferator‐activated receptor‐γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376–380. [DOI] [PubMed] [Google Scholar]
  • 13. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, et al.: Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002; 51: 314–317. [DOI] [PubMed] [Google Scholar]
  • 14. Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T: Adiponectin an adipocyte‐derived protein, predicts future insulin resistance: two‐year follow‐up study in Japanese population. J Clin Endocrinol Metab 2004; 89: 87–90. [DOI] [PubMed] [Google Scholar]
  • 15. Chan KC, Chou HH, Wu DJ, Wu YL, Huang CN: Diabetes mellitus has an additional effect on coronary artery disease: to decrease plasma adiponectin levels. Jpn Heart J 2004; 45: 921–927. [DOI] [PubMed] [Google Scholar]
  • 16. Koh KK: Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000; 47: 648–657. [DOI] [PubMed] [Google Scholar]
  • 17. Koh KK, Cardillo C, Bui MN, Hathaway L, Csako G, et al.: Vascular effects of estrogen and cholesterol‐lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999; 99: 354–360. [DOI] [PubMed] [Google Scholar]
  • 18. Merten M, Dong JF, Lopez JA, Thiagarajan P: Cholesterol sulfate: a new adhesive molecule for patients. Circulation 2001; 103: 2032–2034. [DOI] [PubMed] [Google Scholar]
  • 19. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, et al.: Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 247–251. [DOI] [PubMed] [Google Scholar]
  • 20. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, et al.: Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172–3177. [DOI] [PubMed] [Google Scholar]
  • 21. Jialal I, Stein D, Balis D, Grundy SM, Adams‐Huet B, et al.: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C‐reactive protein levels. Circulation 2001; 103: 1933–1935. [DOI] [PubMed] [Google Scholar]
  • 22. Strandberg TE, Vanhanen H, Tikkanen MJ: Effects of statins on C‐reactive protein in patients with coronary artery disease. Lancet 1999; 353: 188–189. [DOI] [PubMed] [Google Scholar]
  • 23. Kluft C, de Maat MP, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF: Statins and C‐reactive protein. Lancet 1999; 353: 1274. [DOI] [PubMed] [Google Scholar]
  • 24. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long‐term effects of pravastatin on plasma concentration of C‐reactive protein: the Cholesterol and Recurrent Events (CARE) investigators. Circulation 1999; 100: 230–235. [DOI] [PubMed] [Google Scholar]
  • 25. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) investigators. Circulation 1998; 98: 839–844. [DOI] [PubMed] [Google Scholar]
  • 26. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, et al.: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by Atorvastatin, a new HMG‐CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678–682. [DOI] [PubMed] [Google Scholar]
  • 27. Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, et al.: An adipocyte‐derived plasma protein, adiponectin, adheres to injured vascular wall. Horm Metab Res 2000; 32: 47–50. [DOI] [PubMed] [Google Scholar]
  • 28. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, et al.: Plasma concentrations of a novel, adipose‐specific protein, adiponectin, in type 2 diabetes patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595–1599. [DOI] [PubMed] [Google Scholar]
  • 29. Shimada K, Miyauchi K, Mokuno H, Miyazaki T, Seki E, et al.: Predictive value of the adipocyte‐derived plasma protein adiponectin for restenosis after elective coronary stenting. Jpn Heart J 2002; 43: 85–91. [DOI] [PubMed] [Google Scholar]
  • 30. Liao JK: Statins: potent vascular anti‐inflammatory agents. Blackwell Publishing Ltd. Int J Clin Pract 2004; 58: 41–48. [DOI] [PubMed] [Google Scholar]
  • 31. The Scandinavian Simvastatin Survival Study Group : Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1999; 344: 1383–1389. [PubMed] [Google Scholar]
  • 32. The Long‐Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group : Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357. [DOI] [PubMed] [Google Scholar]
  • 33. The Heart Protection Study Collaborative Group : The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: a randomized placebo controlled trial. Lancet 2002; 360: 7–22.12114036 [Google Scholar]
  • 34. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009. [DOI] [PubMed] [Google Scholar]
  • 35. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, et al.: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic hypertensive patients. Circulation 2004; 110: 3687–3692. [DOI] [PubMed] [Google Scholar]
  • 36. Koh KK, Quon MJ, Han SH, Ahn JY, Jin DK, et al.: Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005; 45: 1088–1093. [DOI] [PubMed] [Google Scholar]
  • 37. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, et al.: Additive beneficial effects of fenofibrate combined with Atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005; 45: 1649–1653. [DOI] [PubMed] [Google Scholar]
  • 38. Bayes B, Granada ML, Lauzurica R, Pastor MC, Navarro M, et al.: Effect of low doses of Atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients. Transplant Proc 2005; 37: 3808–3812. [DOI] [PubMed] [Google Scholar]
  • 39. Gannage‐Yared MH, Azar RR, Amm‐Azar M, Khalife S, Germanos‐Haddad M, et al.: Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 2005; 54(7): 947–951. [DOI] [PubMed] [Google Scholar]
  • 40. Sakamoto K, Sakamoto T, Ogawa H, Kumamoto Joint Research on Hypercholesterolemia Investigators : The effect of 6 mo of treatment with pravastatin on serum adiponectin concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study. Clin Ther 2006; 28(7): 1012–1021. [DOI] [PubMed] [Google Scholar]
  • 41. Sonmez A, Dogru T, Tasci I, Yilmaz MI, Pinar M, et al.: The effect of fluvastatin on plasma adiponectin levels in dyslipidemia. Clin Endocrinol (Oxf) 2006; 64(5): 567–572. [DOI] [PubMed] [Google Scholar]
  • 42. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishda M, et al.: Reciprocal association of C‐reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671–674. [DOI] [PubMed] [Google Scholar]
  • 43. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, et al.: Effects of statins on adpocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49(8): 1881–1892. [DOI] [PubMed] [Google Scholar]
  • 44. Chen Y, Ohmori K, Mizukawa M, Yoshida J, Zeng Y, et al.: Differential impact of Atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 2007; 71(1): 144–152. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES